welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Imatinib for Progressive and Recurrent Aggressive Fibromatosis (Desmoid Tumors): An FNCLCC/French Sarcoma Group Phase II Trial With a Long-term Follow-up
source: Annals of oncology
authors: Penel N, Le Cesne A, Bui B N, Perol D, Brain E G, Ray-Coquard I, Guillemet C, Chevreau C, Cupissol D, Chabaud S, Jimenez M, Duffaud F, Piperno-Neumann S, Mignot L, Blay J Ysummary/abstract:
Imatinib evaluated as a new treatment option in patients with recurrent or established progressive aggressive fibromatosis/desmoid tumor (AF/DT).
PATIENTS AND METHODS:
Forty patients with unresectable and progressive symptomatic AF/DT were treated with imatinib (400 mg/day for 1 year) in a Simon’s optimal two-stage phase II study (P(0) = 10%, P(1) = 30%, α = 5%, β = 10%). The primary end point was non-progressive at 3 months (RECIST).
The study population consisted of 28 women and 12 men, with a mean age of 41 (range 20-72 years). Most of the primary sites were extra-abdominal (24, 54.5%). Familial adenomatous polyposis was observed in six (15%) cases. The median follow-up was 34 months. Imatinib toxicity was similar to that previously reported in literature. Tumor assessment was validated by a central independent radiology committee for 35 patients At 3 months, one (3%) complete and three (9%) partial confirmed responses were observed. The non-progression rates at 3, 6 and 12 months were, respectively, 91%, 80% and 67%. The 2-year progression-free and overall survival rates were 55% and 95%, respectively. Two patients with mesenteric AF/DT died from progressive disease.
Imatinib is active in the treatment of recurrent and progressive AF/DT, providing objective response and long-term stable disease in a large proportion of patients.
read more full text source
expertly curated content related to this topic
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Pati...This is a registry-based observation...
Endoscopic Submucosal Dissection to Treat Ileal High-Grade Dysplasia After Ileoanal Anastomosis for Familial Adenoma...Restorative proctocolectomy has become t...
Targeted Therapy for Hereditary Cancer Syndromes: Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Fam...Cancer genetics has rapidly evolved in t...
Barnett Continent Intestinal Reservoir (BCIR) can Replace a Failed J-Pouch or Kock Pouchhttps://www.youtube.com/watch?v=jk4ogi-J...
Chemoprevention in Familial Adenomatous PolyposisFamilial adenomatous polyposis (FAP) pre...
Clinical End Points for Developing Pharmaceuticals to Manage Patients with a Sporadic or Genetic Risk of Colorectal ...To reduce the morbidity and mortality fr...
Sulindac Sulfone is Most Effective in Modulating Beta-Catenin-Mediated Transcription in Cells with Mutant APCSulindac sulfone (FGN-1, Aptosyn), a met...